List of Onglyza drug patents

Onglyza is owned by Astrazeneca Ab.

Onglyza contains Saxagliptin Hydrochloride.

Onglyza has a total of 2 drug patents out of which 0 drug patents have expired.

Onglyza was authorised for market use on 31 July, 2009.

Onglyza is available in tablet;oral dosage forms.

Onglyza can be used as method for treating type ii diabetes by administering saxagliptin; method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.

The generics of Onglyza are possible to be released after 30 November, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7951400 ASTRAZENECA AB Coated tablet formulation and method
Nov, 2028

(5 years from now)

Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea

Dosage: TABLET;ORAL

How can I launch a generic of ONGLYZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in